Gilead Sciences (GILD) : St Germain D J Co Inc scooped up 1,996 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 7,421 shares of Gilead Sciences which is valued at $756,423.Gilead Sciences makes up approximately 0.11% of St Germain D J Co Inc’s portfolio.
Gilead Sciences closed down -0.61 points or -0.60% at $100.72 with 85,85,754 shares getting traded on Wednesday. Post opening the session at $101.3, the shares hit an intraday low of $100.15 and an intraday high of $101.78 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Paradigm Financial Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 642 additional shares and now holds a total of 55,228 shares of Gilead Sciences which is valued at $5,629,390. Gilead Sciences makes up approx 3.41% of Paradigm Financial Advisors’s portfolio.Gemmer Asset Management reduced its stake in GILD by selling 5 shares or 0.4% in the most recent quarter. The Hedge Fund company now holds 1,237 shares of GILD which is valued at $121,585. Gilead Sciences makes up approx 0.07% of Gemmer Asset Management’s portfolio.Guinness Asset Management Ltd boosted its stake in GILD in the latest quarter, The investment management firm added 5,680 additional shares and now holds a total of 25,910 shares of Gilead Sciences which is valued at $2,546,694. Gilead Sciences makes up approx 0.75% of Guinness Asset Management Ltd’s portfolio.Rathbone Brothers Plc reduced its stake in GILD by selling 138,270 shares or 89.45% in the most recent quarter. The Hedge Fund company now holds 16,301 shares of GILD which is valued at $1,562,125. Gilead Sciences makes up approx 0.10% of Rathbone Brothers Plc’s portfolio.
On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.